Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CAI:PHAR's PB Ratio is ranked worse than 65.58% of 921
companies
in the Drug Manufacturers industry
Industry Median: 1.9
vs CAI:PHAR: 2.76
During the past 12 months, Egyptian International Pharmaceutical Investments's average Book Value Per Share Growth Rate was 7.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 10.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 7.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 9.00% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Egyptian International Pharmaceutical Investments was 18.70% per year. The lowest was 2.10% per year. And the median was 6.70% per year.
Back to Basics: PB Ratio
Egyptian International Pharmaceutical Investments (CAI:PHAR) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Egyptian International Pharmaceutical Investments PB Ratio Related Terms
Egyptian International Pharmaceutical Investments PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Egyptian International Pharmaceutical Investments PB Ratio Chart
Egyptian International Pharmaceutical Investments Annual Data
For the Drug Manufacturers - Specialty & Generic subindustry, Egyptian International Pharmaceutical Investments's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Egyptian International Pharmaceutical Investments PB Ratio vs Drug Manufacturers Industry
Egyptian International Pharmaceutical Investments PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Egyptian International Pharmaceutical Investments (CAI:PHAR) has a PB Ratio of 2.76 as of Jul. 28, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Egyptian International Pharmaceutical Investments and its competitors. This is 59% above median its historical median of 1.74. Over the past decade, Egyptian International Pharmaceutical Investments' PB Ratio has ranged from 0.94 to 15.53. According to the industry distribution chart, Egyptian International Pharmaceutical Investments ranks #604 out of 921 companies in the Drug Manufacturers industry, placing it in the top 65.6%.
Is Egyptian International Pharmaceutical Investments' PB Ratio too high?
Egyptian International Pharmaceutical Investments' current PB Ratio of 2.76 is 59% above median its 10-year median of 1.74. Over the past 10 years, this metric has ranged from a low of 0.94 to a high of 15.53. The Drug Manufacturers industry median PB Ratio is 1.90. Egyptian International Pharmaceutical Investments' value of 2.76 is 45.3% above this industry median. Based on the distribution chart, Egyptian International Pharmaceutical Investments ranks #604 out of 921 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Egyptian International Pharmaceutical Investments has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Egyptian International Pharmaceutical Investments' PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Egyptian International Pharmaceutical Investments ranks #604 out of 921 companies for PB Ratio. This places Egyptian International Pharmaceutical Investments in the lower half of its industry. The industry median PB Ratio is 1.90. Egyptian International Pharmaceutical Investments' value of 2.76 is 45.3% above this benchmark. Historically, Egyptian International Pharmaceutical Investments' own PB Ratio has ranged from 0.94 to 15.53 over the past decade. While the company's 10-year median is 1.74 vs. the industry median of 1.90, Egyptian International Pharmaceutical Investments has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.90, based on 921 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Egyptian International Pharmaceutical Investments's current PB Ratio of 2.76 is 45.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Egyptian International Pharmaceutical Investments and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Egyptian International Pharmaceutical Investments's current PB Ratio is 2.76, which is 59% above median its own 10-year median of 1.74. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Egyptian International Pharmaceutical Investments stock overvalued right now?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments (CAI:PHAR) is currently considered Significantly Overvalued. The stock's GF Value™ is E£59.93, compared to a current price of E£92.80 — trading 54.8% above its estimated fair value. The current PB Ratio is 2.76, which is 59% above median its 10-year median of 1.74 and 45.3% above the Drug Manufacturers industry median of 1.90. Egyptian International Pharmaceutical Investments' overall GF Score™ is 73/100 with 12 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Egyptian International Pharmaceutical Investments (CAI:PHAR), the current PB Ratio is 2.76 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Egyptian International Pharmaceutical Investments (CAI:PHAR) Overvalued in 2026?
Based on GuruFocus' analysis, Egyptian International Pharmaceutical Investments stock appears to be overvalued.
The current stock price of E£92.80 is trading 54.8% above its estimated GF Value™ of E£59.93.
GuruFocus considers Egyptian International Pharmaceutical Investments to be Significantly Overvalued.
Key valuation signals for CAI:PHAR:
PB Ratio: 2.76 (59% above median its 10-year median of 1.74)
GF Value™: E£59.93 vs. price of E£92.80 (54.8% above fair value)
Industry Position: 45.3% above the Drug Manufacturers median (#604 of 921)
No single metric tells the full story. See the CAI:PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Egyptian International Pharmaceutical Investments Business Description
Egyptian International Pharmaceutical Investments is an Egypt based company pharmaceutical generic drugs. It holds license agreements with a group of pharmaceutical companies to produce their products locally and replace the imported ones. The company produces dosage forms, Spansule capsules, Antibiotics, Lyophilized Products. It exports its products to African, Asian and East European and Latin American Countries.
73GF Score
Get the complete analysis for CAI:PHAR
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAI:PHAR has been successfully added to your 
